Abstract:Coxsackievirus A10 (CVA10) has recently emerged as one of the major causative agents of hand, foot, and mouth disease. CVA10 may also cause a variety of complications. No approved vaccine or drug is currently available for CVA10. The residues of CVA10 critical for viral attachment, infectivity and in vivo pathogenicity have not been identified by experiment. Here, we report the identification of CVA10 residues important for binding to cellular receptor KREMEN1. We identified VP2 N142 as a key receptor-binding residue by screening of CVA10 mutants resistant to neutralization by soluble KREMEN1 protein. The receptor-binding residue N142 is exposed on the canyon rim but highly conserved in all naturally occurring CVA10 strains, which provides a counterexample to the canyon hypothesis. Residue N142 when mutated drastically reduced receptor-binding activity, resulting in decreased viral attachment and infection in cell culture. More importantly, residue N142 when mutated reduced viral replication in limb muscle and spinal cord of infected mice, leading to lower mortality and less severe clinical symptoms. Additionally, residue N142 when mutated could decrease viral binding affinity to anti-CVA10 polyclonal antibodies and a neutralizing monoclonal antibody and render CVA10 resistant to neutralization by the anti-CVA10 antibodies. Overall, our study highlights the essential role of VP2 residue N142 of CVA10 in the interactions with KREMEN1 receptor and neutralizing antibodies and viral virulence in mice, facilitating the understanding of the molecular mechanisms of CVA10 infection and immunity. Our study also provides important information for rational development of antibody-based treatment and vaccines against CVA10 infection. Coxsackievirus A10 (CVA10) is an emerging pathogen that causes hand, foot, and mouth disease. No approved vaccines or antiviral treatments for CVA10 infection are yet available. Here we identified VP2 N142 of CVA10 as a key residue essential for viral recognition by KREMEN1 receptor by selection of soluble receptor neutralization-resistant mutant and mutational analysis. Residue N142 when mutated could significantly reduce receptor-binding activity, viral attachment, and infection in vitro. Mouse infection experiments show that residue N142 when mutated could reduce fatality rate and severity of symptoms by decreasing viral loads in limb muscle and spinal cord. Furthermore, residue N142 when mutated could confer resistance to neutralization by anti-CVA10 neutralizing antibodies. Additionally, N142, which is exposed on the canyon rim but highly conserved in CVA10, is identified as a key receptor-binding residue, providing a counterexample to the canyon hypothesis. Overall, our findings promote a better understanding of the molecular basis of CVA10 attachment and infection and in vivo pathogenicity, and also provide useful information for rational research and development of vaccines and antibody-based treatment against CVA10 infection.

Identification of a neutralizing linear epitope within the VP1 protein of coxsackievirus A10

Analysis for characteristics of Coxsaekievirus A16 VP1 gene and prediction of B lymphocyte antigen epitopes in Zhejiang province, China

Identification of a Conserved, Linear Epitope on VP3 of Enterovirus A Species Recognized by a Broad-Spectrum Monoclonal Antibody

VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice

Genetic Characteristics of the P1 Coding Region of Coxsackievirus A16 Associated with Hand, Foot, and Mouth Disease in China.

VP1 Sequence Determination and Phylogenetic Analysis of Coxsackievirus A16 Strains

Molecular characteristics of the structure protein VP1 in Coxsackievirus A10 Isolates from China

Molecular mechanism of antibody neutralization of coxsackievirus A16

Rapid and Sensitive Identification of RNA from the Emerging Pathogen, Coxsackievirus A6

Preparation and verification of a monoclonal antibody against a conserved linear epitope in enterovirus A protein 2C

Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody

Characterization of coxsackievirus A10 strains isolated from children with hand, foot, and mouth disease

A Peptide of Foot-and-mouth Disease Virus Serotype Asia1 Generating a Neutralizing Antibody Response, and an Immunostimulatory Peptide

Identification of specific antigenic epitope at N-terminal segment of enterovirus 71 (EV-71) VP1 protein and characterization of its use in recombinant form for early diagnosis of EV-71 infection

Hand-foot-and-mouth disease virus receptor KREMEN1 binds the canyon of Coxsackie Virus A10

Identification of a novel linear B-cell epitope using a monoclonal antibody against the carboxy terminus of the canine distemper virus nucleoprotein and sequence analysis of the identified epitope in different CDV isolates

Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease

Identification of a linear B-cell epitope on the "puff" loop of the Senecavirus A VP2 protein involved in receptor binding

Genome-wide Linear B-cell Epitopes of Enterovirus 71 in a Hand, Foot and Mouth Disease (HFMD) Population

Characterization of Neutralizing Monoclonal Antibodies and Identification of a Novel Conserved C-Terminal Linear Epitope on the Hemagglutinin Protein of the H9N2 Avian Influenza Virus

Comprehensive profiling and characterization of cellular microRNAs in response to coxsackievirus A10 infection in bronchial epithelial cells